Duncan Blythe plans to decrease his weighting to European and global equities over the remainder of this year, while upping 7IM’s allocation to UK stocks.

The fund selector said that over the last 12 months, the investment house has trimmed its position in bond funds and upped its focus on liquid alternatives. There has also been a greater attention on global thematic strategies that focus on climate change and health innovation. This reflects Blyth’s most recent addition to the buy list - Baillie Gifford Health Innovation.  

Blythe has sat on the firm’s diversity and inclusion committee since 2020, and is passionate about closing the gender pay gap within the industry. Elsewhere, he is focused on scrutinising individual managers over a five-year period, as opposed to funds. This means that 7IM has the flexibility to invest in new launches, if run by an established investor.